Four decades of transmission of a multidrug-resistant Mycobacterium tuberculosis outbreak strain

Nature Communications

Volumn 6, Issue , 2015, Pages

  Eldholm, Vegard ^a   Monteserin, Johana ^b   Rieux, Adrien ^c   Lopez, Beatriz ^b   Sobkowiak, Benjamin ^c   Ritacco, Viviana ^b   Balloux, Francois ^c  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b INSTITUTO NACIONAL DE ENFERMEDADES INFECCIOSAS   (Argentina)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ISONIAZID; RIFAMPICIN; STREPTOMYCIN; BACTERIAL PROTEIN; TUBERCULOSTATIC AGENT;

ANTIMICROBIAL ACTIVITY; BACTERIUM; CHEMOTHERAPY; DISEASE TRANSMISSION; DRUG RESISTANCE; PUBLIC HEALTH; TUBERCULOSIS;

ANTIBIOTIC RESISTANCE; ARGENTINA; ARTICLE; BACTERIAL TRANSMISSION; GENE MUTATION; MULTIDRUG RESISTANT MYCOBACTERIUM TUBERCULOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHYLOGENY; DRUG EFFECTS; EPIDEMIC; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PHYSIOLOGY; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; TIME FACTOR; TRANSMISSION; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ARGENTINA;

MYCOBACTERIUM TUBERCULOSIS;

ANTITUBERCULAR AGENTS; ARGENTINA; BACTERIAL PROTEINS; DISEASE OUTBREAKS; GENE EXPRESSION REGULATION, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; PHYLOGENY; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; TIME FACTORS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84929192008     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms8119     Document Type: Article

References (49)

1. World Health Organization. ANTIMICROBIAL RESISTANCE Global Report on Surveillance (WHO, 2014).
2. Mutreja, A. et al. Evidence for several waves of global transmission in the seventh cholera pandemic. Nature 477, 462-465 (2011).
3. Zhou, Z. et al. Transient Darwinian selection in Salmonella enterica serovar Paratyphi A during 450 years of global spread of enteric fever. Proc. Natl Acad. Sci. USA 111, 12199-12204 (2014).
4. Holden, M. T. G. et al. A genomic portrait of the emergence, evolution, and global spread of a methicillin-resistant Staphylococcus aureus pandemic. Genome Res. 23, 653-664 (2013).
5. Uhlemann, A.-C. et al. Molecular tracing of the emergence, diversification, and transmission of S. aureus sequence type 8 in a New York community. Proc. Natl Acad. Sci. USA 111, 6738-6743 (2014).
6. Casali, N. et al. Evolution and transmission of drug-resistant tuberculosis in a Russian population. Nat. Genet. 46, 279-286 (2014).
7. Merker, M. et al. Evolutionary history and global spread of the Mycobacterium tuberculosis Beijing lineage. Nat. Genet. 47, 242-249 (2015).
8. Seear, M. The need for coordinated action against falsified and substandard medicines. Int. J. Tuberc. Lung Dis. 17, 1 (2013).
9. van Soolingen, D., Hermans, P.W., de Haas, P. E., Soll, D. R. & van Embden, J. D. Occurrence and stability of insertion sequences in Mycobacterium tuberculosis complex strains: evaluation of an insertion sequence-dependent DNA polymorphism as a tool in the epidemiology of tuberculosis. J. Clin. Microbiol. 29, 2578-2586 (1991).
10. Allix-Béguec, C., Harmsen, D., Weniger, T., Supply, P. & Niemann, S. Evaluation and strategy for use of MIRU-VNTRplus, a multifunctional database for online analysis of genotyping data and phylogenetic identification of Mycobacterium tuberculosis complex isolates. J. Clin. Microbiol. 46, 2692-2699 (2008).
11. Allix, C. et al. Evaluation of the epidemiological relevance of variable-number tandem-repeat genotyping of Mycobacterium bovis and comparison of the method with IS6110 restriction fragment length polymorphism analysis and spoligotyping. J. Clin. Microbiol. 44, 1951-1962 (2006).
12. Allix-Beguec, C., Fauville-Dufaux, M. & Supply, P. Three-year populationbased evaluation of standardized mycobacterial interspersed repetitive-unitvariable- number tandem-repeat typing of Mycobacterium tuberculosis. J. Clin. Microbiol. 46, 1398-1406 (2008).
13. Walker, T. M. et al. Whole-genome sequencing to delineate Mycobacterium tuberculosis outbreaks: a retrospective observational study. Lancet Infect. Dis. 13, 137-146 (2013).
14. Roetzer, A. et al. Whole genome sequencing versus traditional genotyping for investigation of a Mycobacterium tuberculosis outbreak: a longitudinal molecular epidemiological study. PLoS Med. 10, e1001387 (2013).
15. Walker, T. M. et al. Assessment of Mycobacterium tuberculosis transmission in Oxfordshire, UK, 2007-12, with whole pathogen genome sequences: an observational study. Lancet Resp. Med. 2, 285-292 (2014).
16. Reves, R., Blakey, D., Snider, D. E. & Farer, L. S. Transmission of multiple drug-resistant tuberculosis: report of a school and community outbreak. Am. J. Epidemiol. 113, 423-435 (1981).
17. Cegielski, J. P. Extensively drug-resistant tuberculosis: 'There must be some kind of way out of here'. Clin. Infect. Dis. 50, S195-S200 (2010).
18. Gandhi, N. R. et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368, 1575-1580.
19. Samper, S. & Martin, C. Spread of extensively drug-resistant tuberculosis. Emerg. Infect. Dis. 13, 2 (2007).
20. Ritacco, V. et al. Nosocomial spread of human immunodeficiency virus-related multidrug-resistant tuberculosis in Buenos Aires. J. Infect. Dis. 176, 637-642 (1997).
21. Palmero, D. et al. Multidrug-resistant tuberculosis in HIV-negative patients, Buenos Aires, Argentina. Emerg. Infect. Dis. 9, 965-969 (2003).
22. Ritacco, V. et al. HIV infection and geographically bound transmission of drug-resistant tuberculosis, Argentina. Emerg. Infect. Dis. 18, 1802 (2012).
23. Banerjee, R. et al. Extensively drug-resistant tuberculosis in California, 1993-2006. Clin. Infect. Dis. 47, 450-457 (2008).
24. Coll, F. et al. A robust SNP barcode for typing Mycobacterium tuberculosis complex strains. Nat. Commun. 5, 4812 (2014).
25. Drummond, A. & Rambaut, A. BEAST: Bayesian evolutionary analysis by sampling trees. BMC Evol. Biol. 7, 214 (2007).
26. Heym, B., Alzari, P. M., Honore, N. & Cole, S. T. Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis. Mol. Microbiol. 15, 235-245 (1995).
27. Okamoto, S. et al. Loss of a conserved 7-methylguanosine modification in 16S rRNA confers low-level streptomycin resistance in bacteria. Mol. Microbiol. 63, 1096-1106 (2007).
28. Sandgren, A. et al. Tuberculosis drug resistance mutation database. PLoS. Med. 6, e1000002 (2009).
29. De Kantor, I. N. & Barrera, L. Susceptibility tests to second line drugs and re-treatment of tuberculosis: revisiting early experiences. Medicina (B. Aires) 67, 7 (2007).
30. Huang, W.-L., Chi, T.-L., Wu, M.-H. & Jou, R. Performance assessment of the GenoType MTBDRsl test and DNA sequencing for detection of second-line and ethambutol drug resistance among patients infected with multidrugresistant Mycobacterium tuberculosis. J. Clin. Microbiol. 49, 2502-2508 (2011).
31. Witney, A. A. et al. Clinical application of whole genome sequencing to inform treatment for multi-drug resistant tuberculosis cases. J. Clin. Microbiol. (2015).
32. Miotto, P. et al. Mycobacterium tuberculosis pyrazinamide resistance determinants: a multicenter study. mBio 5, e01819-e01814 (2014).
33. Suzuki, Y. et al. Detection of kanamycin-resistant Mycobacterium tuberculosis by identifying mutations in the 16S rRNA gene. J. Clin. Microbiol. 36, 1220-1225 (1998).
34. Malik, S., Willby, M., Sikes, D., Tsodikov, O. V. & Posey, J. E. New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations. PLoS ONE 7, e39754 (2012).
35. Bernard, C. et al. Molecular diagnosis of fluoroquinolone resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 59, 1519-1524 (2015).
36. Miesel, L., Weisbrod, T. R., Marcinkeviciene, J. A., Bittman, R. & Jacobs, Jr. W. R. NADH dehydrogenase defects confer isoniazid resistance and conditional lethality in Mycobacterium smegmatis. J. Bacteriol. 180, 2459-2467 (1998).
37. Vadwai, V. et al. Can inhA mutation predict ethionamide resistance? Int. J. Tuberc. Lung Dis. 17, 129-130 (2013).
38. Vilcheze, C. et al. Mycothiol biosynthesis is essential for ethionamide susceptibility in Mycobacterium tuberculosis. Mol. Microbiol. 69, 1316-1329 (2008).
39. Comas, I. et al. Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat. Genet. 44, 106-110 (2012).
40. Casali, N. et al. Microevolution of extensively drug-resistant tuberculosis in Russia. Genome Res. 22, 735-745 (2012).
41. Ritacco, V. et al. HIV infection and geographically bound transmission of drugresistant tuberculosis, Argentina. Emerg. Infect. Dis. 18, 9 (2012).
42. Eldholm, V. et al. Evolution of extensively drug-resistant Mycobacterium tuberculosis from a susceptible ancestor in a single patient. Genome Biol. 15, 490 (2014).
43. Gouy, M., Guindon, S. & Gascuel, O. SeaView version 4: a multiplatform graphical user interface for sequence alignment and phylogenetic tree building. Mol. Biol. Evol. 27, 221-224 (2010).
44. Firth, C. et al. Using time-structured data to estimate evolutionary rates of double-stranded DNA viruses. Mol. Biol. Evol. 27, 2038-2051 (2010).
45. Guindon, S. et al. New algorithms and methods to estimate maximumlikelihood phylogenies: assessing the performance of PhyML 3.0. Syst. Biol. 59, 307-321 (2010).
46. Keane, T. M., Creevey, C. J., Pentony, M. M., Naughton, T. J. & Mclnerney, J. O. Assessment of methods for amino acid matrix selection and their use on empirical data shows that ad hoc assumptions for choice of matrix are not justified. BMC Evol. Biol. 6, 29 (2006).
47. Baele, G., Li, W. L. S., Drummond, A. J., Suchard, M. A. & Lemey, P. Accurate model selection of relaxed molecular clocks in Bayesian phylogenetics. Mol. Biol. Evol. 30, 239-243 (2013).
48. World Health Organization. Guidelines for Surveillance of Drug Resistance in Tuberculosis (WHO, 2009).
49. World Health Organization. Policy Guidance on TB Drug Susceptibility Testing (DST) of Second-Line Drugs (WHO, 2008).